PSMA binding is widely used for staging prostate cancer through PET scans, as reported by Fourquet A et al., [23], and in the castration-resistant, late stage of the disease to deliver radioisotopes, such as lutetium or actinium, for treating PCa metastases [24]. Here, FOLH1 is linked to prostate carcinoma.